Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    Asenapine, Olanzapine Effective in Patients With Bipolar 1 Disorder: Presented at WCBP - (DGDispatch)
    FDA: Boxed Warning Required for Varenicline, Buproprion Due to Risk of Suicidal Behaviour - (DGNews)
    Quetiapine Monotherapy Shows Potential in Post-Traumatic Stress Disorder: Presented at WCBP - (DGDispatch)
    Olanzapine Effective for Bipolar Disorder in Naturalistic Setting: Presented at WCBP - (DGDispatch)
    Study Suggests Irritability Should Be Considered When Diagnosing Bipolar Disorder in Children - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
      A Guide to Advances in Pain Management: A Synopsis of Roundtable Discussions
      Recognizing and Managing Psychotic and Mood Disorders in Primary Care
      Challenges of the Comorbid Patient: Evaluating Common Comorbidities in Adults and Children/Adolescents and Treatment Considerations
      Mixed States: Practical Application of Evidence, Guidelines, and Clinical Judgment
      Hypomania: The Clinical Reality of Diagnosing Adult and Child/Adolescent Patients

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Female Sexual Dysfunction as a Comorbid Illness
        11p Microdeletion Including WT1 but not PAX6, Presenting with Cataract, Mental Retardation, Genital Abnormalities and Seizures: Case Report
        Comorbidity of Asperger's Syndrome and Bipolar Disorder
        Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
        Treating Bipolar Disorder in Patients with Renal Failure Having Haemodialysis: Two Case Reports

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Aripiprazole Decreases Symptoms of Mania in Paediatric Bipolar Disorder: Presented at AACAP

        By Maria Bishop

        BOSTON, MA -- November 1, 2007 -- Children and adolescents at the onset of bipolar disorder may achieve improvements in manic symptoms with aripiprazole, according to research presented here at the 54th Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP).

        Lead author Kiki D. Chang, MD, Assistant Professor and Director, Pediatric Mood Disorders Clinic, Child and Adolescent Psychiatry, Stanford University School of Medicine, Stanford, California, United States, and colleagues undertook a 54-centre, 4-week study of 296 patients 10 to 17 years of age with bipolar disease.

        Patients in the study were randomised to aripiprazole 10 mg (n = 98) or 30 mg (n = 99), or placebo (n = 99). The primary endpoint was mean baseline total score change in the Young Mania Rating Scale (YMRS).

        Mean change from baseline to week 4 results in the 10-mg arm and the 30-mg arm demonstrated statistically significant improvements over results from the placebo arm, with approximately 17-point and 14-point reductions for treated patients versus an approximate 7 point-reduction for placebo subjects.

        This trial was preceded by a washout period, although benzodiazepines and anticholinergics were allowed during the trial, if necessary.

        Recent reports have claimed that the average age of onset for bipolar disorder is less than 13 years, Dr. Chang noted. The mean age of subjects in this trial was 13.43 years, with the vast majority being older than 12 years.

        There is a paucity of trial data in this patient population, which is traditionally treated for bipolar disorder 1 with lithium, anticonvulsants and atypical antipsychotics, Dr. Chang said.

        Aripiprazole is currently indicated for the treatment of acute manic and mixed episodes associated with bipolar 1 disorder in adults, and for maintaining efficacy in stable patients with bipolar disorder who have had a recent manic or mixed episode.

        Funding for this study was provided by Otsuka Pharmaceutical Co., Ltd.


        [Presentation title: Efficacy of Aripiprazole in Children (10-17) Years Old With Mania: Abstract B6]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send